Navigation Links
Abbott Launches New Instrument to Complete Family of ARCHITECT Immunochemistry Analyzers
Date:7/21/2009

CHICAGO, July 21 /PRNewswire-FirstCall/ -- Today at the American Association for Clinical Chemistry's Clinical Lab Expo in Chicago, Abbott (NYSE: ABT) announced the launch of a new diagnostic instrument -- the ARCHITECT(R) c4000(R) clinical chemistry analyzer which performs diagnostic tests that monitor general health including a patient's levels of sodium, potassium, chloride and organ function.

The new ARCHITECT c4000 seamlessly integrates with Abbott's i1000SR immunoassay analyzer to form the ARCHITECT ci4100(TM), an automated analyzer that completes both immunoassay and chemistry tests on one platform. With these two products, Abbott now offers chemistry, immunoassay, and integrated diagnostic testing solutions to improve the performance and efficiency of laboratories of all sizes.

Abbott is the only company offering high, medium and low-volume integrated diagnostic testing solutions that leverage the same software, reagents and sample carriers. Standardizing to a single family of instruments like Abbott's ARCHITECT products gives labs the ability to optimize processes, minimize errors, and reduce result variability, which is becoming increasingly important as clinicians rely more and more on laboratory diagnostics to guide their treatment decisions.

Abbott's family of ARCHITECT instruments generates accurate and equivalent results across instruments and labs, even at multiple sites, because these instruments share detection technologies, reagents, and software. This standardization is critical as hospitals and the Obama administration continue to emphasize the importance of capturing patient histories in electronic medical records. In a recent study of U.S. hospitals, 73 percent of health care decision makers and executives identified electronic medical records (EMR) as one of their top priorities for 2009.

"Standardized results across laboratory instruments is increasingly important as the reputation of the laboratory and its influence on quality healthcare depends on providing consistent, fast and accurate results to enable the medical staff on site and in other locations to make critical treatment decisions," said Michael Warmuth, senior vice president, diagnostics, Abbott. "We're pleased that Abbott can meet these and other critical needs of laboratories through our complete family of ARCHITECT products."

In addition to standardization across instruments, Abbott's ARCHITECT c4000 and ci4100 are designed to deliver improved productivity to lower volume laboratories. The c4000 analyzer can generate up to 800 test results per hour while the ci4100 integrated system can generate up to 900 test results per hour. With an extensive menu of diagnostic tests and a large sample and reagent load-up capacity, the ARCHITECT c4000 and ci4100 can consolidate a laboratory's workload to increase efficiency and save costs. ARCHITECT instruments are simple to operate with advanced sample management capabilities from the innovative three-dimensional Robotic Sample Handler. With this feature, once manual steps are now automated, which saves laboratories time and money and better meets their increased testing demands.

In addition, Abbott's integrated instruments are the only products on the market that feature no clinically significant sample-to-sample carryover, less than 0.1 parts per million, without resorting to unnecessary sample handling, plastic disposables like pipette tips or extended processing times due to the risk of contamination.

"We evaluated the ARCHITECT c4000 with one of our partner laboratories and found that the ARCHITECT c4000 provides laboratory efficiencies with commonality and equivalent results across the family," said Rob Kerekes, chemistry charge technologist at Huron-Perth Healthcare Alliance in Stratford, Ontario, Canada. "The c4000 is ideal for laboratories requiring a reliable analyzer that takes up less space."

About the ARCHITECT Instrument Family

The ARCHITECT family of analyzers includes the i1000SR and i2000SR for immunoassay testing, the c4000, c8000, and c16000 for clinical chemistry testing, and the ci4100, ci8200, and ci16200 integrated immunoassay/chemistry systems. Abbott's unique technologies include the Robotic Sample Handler to prioritize emergency tests; sample clot and bubble detection to verify sampling integrity; and FlexRate and CHEMIFLEX assay technologies. ARCHITECT systems use identical easy-to-use software and common reagents across all members of the family, ensuring fast and accurate results while requiring a very small sample volume, resulting in improved performance. These features not only save laboratories' time by reducing the time needed for instrument training, testing and troubleshooting, but also reduce inventory costs and reduce the potential for sample contamination -- leading to better results for laboratories, physicians and, ultimately, patients.

About Abbott Diagnostics

Abbott Diagnostics is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, blood banks, physician offices and clinics. With more than 69,000 institutional customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnostics from an art to a science through the company's commitment to improving patient care and lowering overall costs. The history of Abbott Diagnostics is filled with examples of first-of-a-kind products and significant technological advancements, including the development of the very first diagnostic test to detect HIV.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

ARCHITECT, i1000SR, i2000SR, c4000, c8000, c16000, ci4100, ci8200, ci16200, CHEMIFLEX and FlexRate are trademarks of Abbott Laboratories.


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
Breaking Medicine Technology: